IMMULITE/IMMULITE 1000 AFP AND IMMULITE 2000/IMMULITE 2500 AFP
Siemens Healthcare Diagnostics, Inc. · Decision date Nov 9, 2001
What did the FDA approve?
FDA approved the IMMULITE AFP for the IMMULITE analyzer and IMMULITE 2000 AFP for the IMMULITE 2000 analyzer on November 9, 2001. The devices quantitatively measure alpha-fetoprotein in serum for serial monitoring of patients with nonseminomatous testicular cancer, or in maternal serum and amniotic fluid at gestational weeks 15 through 20, with ultrasonography or amniography, to aid detection of fetal open neural tube defects.
The decision is an original PMA approval, not a supplement. The statement describes the intended diagnostic uses but does not provide independent evidence of safety or clinical effectiveness. Specific information absent from the record includes any clinical trial data, performance metrics, or labeling details beyond the stated indications.
FDA approval order statement
APPROVAL FOR IMMULITE AFP FOR USE WITH THE IMMULITE ANALYZER AND IMMULITE 2000 AFP FOR USE WITH THE IMMULITE 2000 ANALYZER. THESE DEVICES ARE INDICATED FOR IN VITRO DIAGNOSTIC USE FOR THE QUANTITATIVE MEASUREMENT OF ALPHA-FETOPROTEIN (AFP) IN EITHER OF TWO CONTEXTS: A) SERIAL MEASUREMENTS IN HUMAN SERUM TO AID IN THE MANAGEMENT OF PATIENTS WITH NONSEMINOMATOUS TESTICULAR CANCER: OR B) MEASUREMENT IN MATERNAL SERUM AND AMNIOTIC FLUID DURING GESTATIONAL WEEKS 15 THROUGH 20 - USED IN CONJUNCTION WITH ULTRASONOGRAPHY OR AMNIOGRAPHY - TO AID IN DETECTION OF FETAL OPEN NEURAL TUBE DEFECTS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Immunology
- Decision date
- Nov 9, 2001
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010007
- Regulatory pathway
- Premarket approval application
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- LOK
- Decision code
- APPR
- Decision date
- Nov 9, 2001
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- LOK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P010007 received
Application receipt date recorded by FDA.
P010007 · FDA decision
APPR
P010007/S024 · Related supplement
IMMULITE 2000 AFP
P010007/S025 · Related supplement
IMMULITE 2000 AFP
P010007/S026 · Related supplement
IMMULITE 2000 AFP
P010007/S027 · Related supplement
IMMULITE Systems AFP
P010007/S028 · Related supplement
IMMULITE Systems AFP
Timeline entries are records held by MedtechLedger for P010007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE 2000 AFPP010007/S024 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 30, 2025 | FDA |
IMMULITE 2000 AFPP010007/S025 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
IMMULITE 2000 AFPP010007/S026 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
IMMULITE Systems AFPP010007/S027 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE Systems AFPP010007/S028 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code LOK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S032 | ABBOTT LABORATORIES | PMA supplement | May 11, 2026 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | May 11, 2026 | FDA | |
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S031 | ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA |
Access AFP (on DxI 9000 Analyzer)P980041/S051 | BECKMAN COULTER, INC. | PMA supplement | Nov 3, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- 511 Benedict Ave., Tarrytown, NY, 10591
Sources and methodology
- Original FDA record: P010007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





